Science news brief
‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
NEWS DESKScience
PUBLISHEDOct 23, 2026, 4:27 AM
What the source reports
Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way Get our new political email , free app or daily news podcast A personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show.
The vaccine, intismeran, is custom-made to target genetic…
Main source: The Guardian Science
TDBN presents the written preview supplied through the publisher's feed. Complete reporting, continuing updates, context, and corrections remain with the original report.
Read the complete report ↗